Panel discussion at the RI-MUHC marks International Day of People Living with Disabilities
Experts and advocates joined the RI-MUHC community to discuss integrating people with disabilities into work...
Significant funding to maximize access and drive excellence in clinical trials in Quebec and Canada
RI-MUHC researchers will lead or co-lead multiple projects awarded a total of $55 million from the Canadian Institutes...
Triple-negative breast cancer: the RI-MUHC enrolls first patients in international Phase 3 clinical trial
The first participants in this large study were recently selected at the Cedars Cancer Centre of the MUHC.
The 2022 RI-MUHC Annual Report is online!
An invitation from Dr. Rhian Touyz
An Equity, Diversity and Inclusion Action Plan for the RI-MUHC
The plan prioritizes six groups traditionally underrepresented in research
Summer Student Research Day returns to the RI-MUHC
A diverse group of young research trainees present their summer projects
A first large detailed description of the worldwide 2022 monkeypox outbreak
MUHC physicians made important contributions to a new article published in the New England Journal of Medicine
Immunotherapy showing significant advancements in lung cancer treatment
Phase 3 clinical trial of neoadjuvant nivolumab leads to practice-changing results
TB and COVID-19, a joint battle?
On World TB Day 2022, we are looking at how researchers from the McGill International TB Centre at the RI-MUHC are working to raise awareness and to put an end to TB.
What’s the signature of a healthy heart?
Instead of treating the “average person,” the Courtois Cardiovascular Signature Program aims to treat every person as a unique individual